Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963548 | 0.87 | CA12 (0.47) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL966590 | 0.84 | CA12 (0.49) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL966298 | 0.83 | CA12 (0.50) | HSD11B1MEN1KMT2ACA12CA9 | |
| SCHEMBL962182 | 0.80 | L3MBTL1 (0.48) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL963552 | 0.80 | MEN1 (0.46) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL964699 | 0.78 | GBA1 (0.50) | HSD11B1MEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL963233 | 0.77 | MEN1 (0.44) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL964483 | 0.77 | MEN1 (0.44) | HSD11B1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL963199 | 0.75 | GAA (0.46) | MEN1KMT2ARAB9ALMNAMAPT | |
| SCHEMBL966612 | 0.75 | BCL2L1 (0.48) | MEN1KMT2ANPC1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | HSD11B1 315/4885MEN1 4766/4885KMT2A 2017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.